ReviewFuture oncology (London, England)2026

Rucaparib - drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.

Alan Haruo Bryce et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.